PMID- 29555439
OWN - NLM
STAT- MEDLINE
DCOM- 20180924
LR  - 20180924
IS  - 1873-3476 (Electronic)
IS  - 0378-5173 (Linking)
VI  - 542
IP  - 1-2
DP  - 2018 May 5
TI  - Current development in the formulations of non-injection administration of 
      paclitaxel.
PG  - 242-252
LID - S0378-5173(18)30177-7 [pii]
LID - 10.1016/j.ijpharm.2018.03.030 [doi]
AB  - Paclitaxel (PTX) belongs to a class of taxane anti-tumor drug used for the clinic 
      treatment of breast cancer, ovarian cancer, non-small-cell lung cancer, and so 
      on. PTX has poor water solubility and oral bioavailability. It is generally 
      administered via intravenous (i.v.) infusion. Traditional PTX injectable 
      preparations contain Cremophor-EL and ethanol to improve its solubility, which 
      would result in adverse reactions like severe hypersensitivity, neutropenia, etc. 
      Adverse reactions can be reduced only by complicated pretreatment with 
      glucocorticoid and antihistamines drugs and followed by PTX slow infusion for 
      three hours, which has brought significant inconvenience to the patients. Though, 
      a new-generation PTX formulation, Abraxane, free of Cremophor-EL and ethanol, is 
      still being administrated by frequent i.v. infusions and extremely expensive. 
      Therefore, non-injection administration of PTX is urgently needed to avoid the 
      side effects as well as reduce inconvenience to the patients. Recently, a variety 
      of non-injection drug delivery systems (DDSs) of PTX have been developed. This 
      review aims to discuss the progress of non-injectable administration systems of 
      PTX, including oral administration systems, vaginal administration systems, 
      implantable DDSs, transdermal DDSs and intranasal administration for the future 
      study and clinical applications.
CI  - Copyright (c) 2018 Elsevier B.V. All rights reserved.
FAU - Du, Xiyou
AU  - Du X
AD  - Department of Pharmaceutics, College of Pharmacy, Shandong University, Jinan 
      250012, China.
FAU - Khan, Abdur Rauf
AU  - Khan AR
AD  - Department of Pharmaceutics, College of Pharmacy, Shandong University, Jinan 
      250012, China.
FAU - Fu, Manfei
AU  - Fu M
AD  - Department of Pharmaceutics, College of Pharmacy, Shandong University, Jinan 
      250012, China.
FAU - Ji, Jianbo
AU  - Ji J
AD  - Department of Pharmaceutics, College of Pharmacy, Shandong University, Jinan 
      250012, China.
FAU - Yu, Aihua
AU  - Yu A
AD  - Department of Pharmaceutics, College of Pharmacy, Shandong University, Jinan 
      250012, China.
FAU - Zhai, Guangxi
AU  - Zhai G
AD  - Department of Pharmaceutics, College of Pharmacy, Shandong University, Jinan 
      250012, China. Electronic address: professorgxzhai@126.com.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20180316
PL  - Netherlands
TA  - Int J Pharm
JT  - International journal of pharmaceutics
JID - 7804127
RN  - 0 (Antineoplastic Agents, Phytogenic)
RN  - P88XT4IS4D (Paclitaxel)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents, Phytogenic/*administration & dosage/chemistry
MH  - Drug Administration Routes
MH  - Drug Compounding
MH  - Drug Delivery Systems
MH  - Humans
MH  - Paclitaxel/*administration & dosage/chemistry
OTO - NOTNLM
OT  - Adverse reactions
OT  - Nanocarriers
OT  - Non-injection administration
OT  - PTX
EDAT- 2018/03/21 06:00
MHDA- 2018/09/25 06:00
CRDT- 2018/03/21 06:00
PHST- 2018/02/08 00:00 [received]
PHST- 2018/03/13 00:00 [revised]
PHST- 2018/03/15 00:00 [accepted]
PHST- 2018/03/21 06:00 [pubmed]
PHST- 2018/09/25 06:00 [medline]
PHST- 2018/03/21 06:00 [entrez]
AID - S0378-5173(18)30177-7 [pii]
AID - 10.1016/j.ijpharm.2018.03.030 [doi]
PST - ppublish
SO  - Int J Pharm. 2018 May 5;542(1-2):242-252. doi: 10.1016/j.ijpharm.2018.03.030. 
      Epub 2018 Mar 16.